Skip to main content
TipRanks
Go Ultimate75% OFF

Phathom Pharmaceuticals (PHAT) Stock Price & Analysis

608 Followers

PHAT Stock Chart & Stats

$4.66-$0.42(-8.27%)
At close: 4:00 PM EST
$5$7.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$4.62 - $5.15
52-Week Range
$4.62 - $18.31
Previous Close
$5.08
Volume
N/A
Average Volume (3M)
1.69M
Market Cap
$412.96M
Enterprise Value
$990.61M
Total Cash (Recent Filing)
$184.56M
Total Debt (Recent Filing)
$167.96M
Price to Earnings (P/E)
―
Beta
2.16
Next Earnings
Mar 02, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth And Improving Operating Profitability

Strong revenue growth combined with consecutive operating profitability indicates that VOQUEZNA is gaining commercial traction and that fixed commercial costs may be increasingly leveraged. If this pattern persists, improving scale could support a more durable transition toward profitability and internally funded growth.

Growing Prescription Base And Broad Payer Coverage

A large and expanding prescription base provides evidence of sustained product adoption rather than reliance on a small initial customer group. Broad commercial coverage can reduce reimbursement barriers, support continued physician prescribing, and improve the franchise’s ability to compound revenue over the next several quarters.

Cash Position Supports Continued Commercial Investment

Cash materially above the financing covenant gives Phathom room to continue commercializing VOQUEZNA and fund development activities without an immediate need for another debt or equity raise. That flexibility is important while management works toward durable positive cash flow in 2027.

Bears Say

Persistent Net Losses And Negative Cash Generation

Despite strong product-level gross margins and improving quarterly results, Phathom remains meaningfully unprofitable and cash-flow negative on a trailing basis. Continued losses consume financial resources, making the planned 2027 cash-flow inflection important and leaving execution dependent on sustaining revenue growth and expense discipline.

Deeply Negative Shareholder Equity

Deeply negative equity reflects the cumulative impact of prior losses and limits balance-sheet flexibility even though latest reported debt was low. This capital structure leaves less capacity to absorb setbacks, increases dependence on successful commercialization, and could constrain future financing and capital-allocation choices.

Regulatory Litigation Threatens Exclusivity Visibility

The litigation creates uncertainty around the timing and durability of VOQUEZNA’s asserted protection through May 3, 2032. An adverse regulatory or legal outcome could accelerate generic competition, weaken future revenue visibility, and reduce the commercial value of Phathom’s primary product franchise.

Phathom Pharmaceuticals News

PHAT FAQ

What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $4.62 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $412.96M.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 101 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Oct 29, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.121 by -$0.039.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -0.09.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 81,291,520 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.121. Following the earnings report the stock price went down -0.955%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Hedge funds hold Phathom Pharmaceuticals shares: the largest hedge-fund position in Phathom Pharmaceuticals is 72,326,075 shares, and hedge funds decreased their holdings by 65.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology